Viva Biotech Holdings (1873) Announces Grant of 8.58 Million Share Options

Bulletin Express12-02

Viva Biotech Holdings (1873) issued an announcement on December 2, 2025, regarding the grant of 8,580,000 share options to employees under its Post-IPO Share Option Scheme. The exercise price was set at HK$2.05 per share, aligning with the listed criteria and quoted market prices on the grant date.

According to the announcement, the share options remain valid until March 30, 2031, with a phased vesting schedule tied to both the Group’s overall performance and individual grantee targets. Key performance benchmarks include revenue growth of 35%, 55%, and 75% in the 2027, 2028, and 2029 financial years, respectively, compared to 2025 levels. All grantees are employees involved in the Group’s contract development and manufacturing operations.

Following this share option issue, the total number of shares remaining available for future grants under the scheme stands at 119,845,000. The Board noted that no additional clawback mechanism was deemed necessary, as existing provisions under the Post-IPO Share Option Scheme already address potential lapses and cancellations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166395462?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166395462","market":"us","top_or_hot":-1,"title":"Viva Biotech Holdings (1873) Announces Grant of 8.58 Million Share Options","media":"Bulletin Express","content":"<p>Viva Biotech Holdings (1873) issued an announcement on December 2, 2025, regarding the grant of 8,580,000 share options to employees under its Post-IPO Share Option Scheme. The exercise price was set at HK$2.05 per share, aligning with the listed criteria and quoted market prices on the grant date.</p>\n<p>According to the announcement, the share options remain valid until March 30, 2031, with a phased vesting schedule tied to both the Group’s overall performance and individual grantee targets. Key performance benchmarks include revenue growth of 35%, 55%, and 75% in the 2027, 2028, and 2029 financial years, respectively, compared to 2025 levels. All grantees are employees involved in the Group’s contract development and manufacturing operations.</p>\n<p>Following this share option issue, the total number of shares remaining available for future grants under the scheme stands at 119,845,000. The Board noted that no additional clawback mechanism was deemed necessary, as existing provisions under the Post-IPO Share Option Scheme already address potential lapses and cancellations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech Holdings (1873) Announces Grant of 8.58 Million Share Options</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech Holdings (1873) Announces Grant of 8.58 Million Share Options\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-02 19:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings (1873) issued an announcement on December 2, 2025, regarding the grant of 8,580,000 share options to employees under its Post-IPO Share Option Scheme. The exercise price was set at HK$2.05 per share, aligning with the listed criteria and quoted market prices on the grant date.</p>\n<p>According to the announcement, the share options remain valid until March 30, 2031, with a phased vesting schedule tied to both the Group’s overall performance and individual grantee targets. Key performance benchmarks include revenue growth of 35%, 55%, and 75% in the 2027, 2028, and 2029 financial years, respectively, compared to 2025 levels. All grantees are employees involved in the Group’s contract development and manufacturing operations.</p>\n<p>Following this share option issue, the total number of shares remaining available for future grants under the scheme stands at 119,845,000. The Board noted that no additional clawback mechanism was deemed necessary, as existing provisions under the Post-IPO Share Option Scheme already address potential lapses and cancellations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1166395462","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166395462","pubTimestamp":1764674652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings (1873) issued an announcement on December 2, 2025, regarding the grant of 8,580,000 share options to employees under its Post-IPO Share Option Scheme. The exercise price was set...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物控股(1873)公布授出858万份购股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings (1873) issued an announcement on December 2, 2025, regarding the grant of 8,580,000 share options to employees under its Post-IPO Share Option Scheme. The exercise price was set at HK$2.05 per share, aligning with the listed criteria and quoted market prices on the grant date.\nAccording to the announcement, the share options remain valid until March 30, 2031, with a phased vesting schedule tied to both the Group’s overall performance and individual grantee targets. Key performance benchmarks include revenue growth of 35%, 55%, and 75% in the 2027, 2028, and 2029 financial years, respectively, compared to 2025 levels. All grantees are employees involved in the Group’s contract development and manufacturing operations.\nFollowing this share option issue, the total number of shares remaining available for future grants under the scheme stands at 119,845,000. The Board noted that no additional clawback mechanism was deemed necessary, as existing provisions under the Post-IPO Share Option Scheme already address potential lapses and cancellations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166395462","isCrawlerRequest":true}